Reata Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
RETA Reata Pharmaceuticals Inc
EW Edwards Lifesciences Corp
COP ConocoPhillips
FBP First Bancorp
PTCT PTC Therapeutics Inc
ROKU Roku Inc
WORK Slack Technologies Inc
ARKW ARK Next Generation Internet ETF
SPOT Spotify Technology SA
GBTC Grayscale Bitcoin Trust (BTC)
Go

Health Care : Pharmaceuticals | Small Cap Value
Company profile

Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases. The Company's lead product candidates include bardoxolone methyl, which is being studied in Phase III trial for the treatment of pulmonary arterial hypertension (PAH), associated with connective tissue disease (CTD-PAH), as well as a Phase II trial for the treatment of pulmonary hypertension due to interstitial lung disease (PH-ILD), and PAH, each of which are subsets of pulmonary hypertension (PH), Omaveloxolone, which is in Phase II clinical development for the treatment of multiple diseases, including Friedreich's ataxia, mitochondrial myopathies and metastatic melanoma.

Closing Price
$111.93
Day's Change
-8.07 (-6.72%)
Bid
--
Ask
--
B/A Size
--
Day's High
121.72
Day's Low
111.80
Volume
(Heavy Day)
Volume:
399,079

10-day average volume:
270,032
399,079

RETA's position in the Pharmaceuticals industry

Industry PeersRETALLYBMYCDXI

Summary

Company ProfileReata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of...
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health...
Go to LLY summary
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products...
Go to BMY summary
Cardax, Inc. is a life sciences company. The Company develops consumer health and pharmaceutical technologies. The Company is engaged in developing and commercializing anti-inflammatory dietary...
Go to CDXI summary
52-Week Change

VS. INDUSTRY
-48.25%
34.89%
-0.36%
-82.95%
Market Cap

VS. INDUSTRY
$4.5B
$171.0B
$147.9B
$1.2M
Beta

VS. INDUSTRY
1.6
0.3
0.6
1.2
Dividend Yield

VS. INDUSTRY
--
1.78%
2.95%
--
P/E (TTM, GAAP)

VS. INDUSTRY
--
29.28x
--
--
Data as of

Fundamentals

Total Revenue (TTM)

VS. INDUSTRY
$8.5M
$23.2B
$39.4B
$615.3K
Profit Margin

VS. INDUSTRY
-4,341.23%
24.01%
-0.07%
-893.89%
Earnings Growth
(5 year, GAAP)

VS. INDUSTRY
--
17.37%
10.85%
--
Revenue Growth (TTM)

VS. INDUSTRY
-73.69%
6.28%
62.97%
-24.55%
Data as of
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Copyright © 2021. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.